 | • レポートコード：D005-08474 • 出版社/出版日：GlobalInfoResearch / 2020年5月22日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、不活化ワクチンの世界市場を広く調査・分析し、今後の市場展望をまとめております。不活化ワクチンの種類別市場規模（）、用途別市場規模（病院、医療センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Astellas Pharma (Japan)、Pfizer (U.S.)、GlaxoSmithKline (U.K.)、CSL Limited (Australia)、Merck & Co (U.S.)、Emergent BioSolutions (U.S.)、Serum Institute of India Pvt (India)、MedImmune (U.S.)、Johnson & Johnson (U.S.)、Sanofi Pasteur (France) ・地域別グローバル市場分析 2015年-2020年 ・不活化ワクチンの北米市場（アメリカ、カナダ、メキシコ） ・不活化ワクチンのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・不活化ワクチンのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・不活化ワクチンの南米市場（ブラジル、アルゼンチン） ・不活化ワクチンの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析： ・用途別分析：病院、医療センター ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Inactivated Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.2% in the forecast period of 2020 to 2025 and will expected to reach USD 6752.5 million by 2025, from USD 5952.8 million in 2019.
The Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Inactivated Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Inactivated Vaccine market has been segmented into
By Application, Inactivated Vaccine has been segmented into:
Hospital
Medical Center
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Inactivated Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level Inactivated Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Inactivated Vaccine market.
The report offers in-depth assessment of the growth and other aspects of the Inactivated Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Inactivated Vaccine Market Share Analysis
Inactivated Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Inactivated Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Inactivated Vaccine sales, revenue and market share for each player covered in this report.
The major players covered in Inactivated Vaccine are:
Astellas Pharma (Japan)
Pfizer (U.S.)
GlaxoSmithKline (U.K.)
CSL Limited (Australia)
Merck & Co (U.S.)
Emergent BioSolutions (U.S.)
Serum Institute of India Pvt (India)
MedImmune (U.S.)
Johnson & Johnson (U.S.)
Sanofi Pasteur (France)
Among other players domestic and global, Inactivated Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Inactivated Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Inactivated Vaccine, with price, sales, revenue and global market share of Inactivated Vaccine in 2018 and 2019.
Chapter 3, the Inactivated Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Inactivated Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Inactivated Vaccine market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Inactivated Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Inactivated Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Inactivated Vaccine Revenue by Type: 2015 VS 2019 VS 2025
1.3 Market Analysis by Application
1.3.1 Overview: Global Inactivated Vaccine Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Medical Center
1.4 Overview of Global Inactivated Vaccine Market
1.4.1 Global Inactivated Vaccine Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma (Japan)
2.1.1 Astellas Pharma (Japan) Details
2.1.2 Astellas Pharma (Japan) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Pharma (Japan) SWOT Analysis
2.1.4 Astellas Pharma (Japan) Product and Services
2.1.5 Astellas Pharma (Japan) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer (U.S.)
2.2.1 Pfizer (U.S.) Details
2.2.2 Pfizer (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer (U.S.) SWOT Analysis
2.2.4 Pfizer (U.S.) Product and Services
2.2.5 Pfizer (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 GlaxoSmithKline (U.K.)
2.3.1 GlaxoSmithKline (U.K.) Details
2.3.2 GlaxoSmithKline (U.K.) Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 GlaxoSmithKline (U.K.) SWOT Analysis
2.3.4 GlaxoSmithKline (U.K.) Product and Services
2.3.5 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 CSL Limited (Australia)
2.4.1 CSL Limited (Australia) Details
2.4.2 CSL Limited (Australia) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 CSL Limited (Australia) SWOT Analysis
2.4.4 CSL Limited (Australia) Product and Services
2.4.5 CSL Limited (Australia) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Merck & Co (U.S.)
2.5.1 Merck & Co (U.S.) Details
2.5.2 Merck & Co (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Merck & Co (U.S.) SWOT Analysis
2.5.4 Merck & Co (U.S.) Product and Services
2.5.5 Merck & Co (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Emergent BioSolutions (U.S.)
2.6.1 Emergent BioSolutions (U.S.) Details
2.6.2 Emergent BioSolutions (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Emergent BioSolutions (U.S.) SWOT Analysis
2.6.4 Emergent BioSolutions (U.S.) Product and Services
2.6.5 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Serum Institute of India Pvt (India)
2.7.1 Serum Institute of India Pvt (India) Details
2.7.2 Serum Institute of India Pvt (India) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Serum Institute of India Pvt (India) SWOT Analysis
2.7.4 Serum Institute of India Pvt (India) Product and Services
2.7.5 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 MedImmune (U.S.)
2.8.1 MedImmune (U.S.) Details
2.8.2 MedImmune (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 MedImmune (U.S.) SWOT Analysis
2.8.4 MedImmune (U.S.) Product and Services
2.8.5 MedImmune (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Johnson & Johnson (U.S.)
2.9.1 Johnson & Johnson (U.S.) Details
2.9.2 Johnson & Johnson (U.S.) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Johnson & Johnson (U.S.) SWOT Analysis
2.9.4 Johnson & Johnson (U.S.) Product and Services
2.9.5 Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Sanofi Pasteur (France)
2.10.1 Sanofi Pasteur (France) Details
2.10.2 Sanofi Pasteur (France) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Sanofi Pasteur (France) SWOT Analysis
2.10.4 Sanofi Pasteur (France) Product and Services
2.10.5 Sanofi Pasteur (France) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Inactivated Vaccine Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Inactivated Vaccine Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Inactivated Vaccine Manufacturer Market Share in 2019
3.3.2 Top 6 Inactivated Vaccine Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Inactivated Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Inactivated Vaccine Sales and Market Share by Regions (2015-2020)
4.1.2 Global Inactivated Vaccine Revenue and Market Share by Regions (2015-2020)
4.2 North America Inactivated Vaccine Sales and Growth Rate (2015-2020)
4.3 Europe Inactivated Vaccine Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Inactivated Vaccine Sales and Growth Rate (2015-2020)
4.5 South America Inactivated Vaccine Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Inactivated Vaccine Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Inactivated Vaccine Sales, Revenue and Market Share by Country
5.1.1 North America Inactivated Vaccine Sales and Market Share by Country (2015-2020)
5.1.2 North America Inactivated Vaccine Revenue and Market Share by Country (2015-2020)
5.2 United States Inactivated Vaccine Sales and Growth Rate (2015-2020)
5.3 Canada Inactivated Vaccine Sales and Growth Rate (2015-2020)
5.4 Mexico Inactivated Vaccine Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Inactivated Vaccine Sales, Revenue and Market Share by Country
6.1.1 Europe Inactivated Vaccine Sales and Market Share by Country (2015-2020)
6.1.2 Europe Inactivated Vaccine Revenue and Market Share by Country (2015-2020)
6.2 Germany Inactivated Vaccine Sales and Growth Rate (2015-2020)
6.3 UK Inactivated Vaccine Sales and Growth Rate (2015-2020)
6.4 France Inactivated Vaccine Sales and Growth Rate (2015-2020)
6.5 Russia Inactivated Vaccine Sales and Growth Rate (2015-2020)
6.6 Italy Inactivated Vaccine Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Inactivated Vaccine Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Inactivated Vaccine Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Inactivated Vaccine Revenue and Market Share by Regions (2015-2020)
7.2 China Inactivated Vaccine Sales and Growth Rate (2015-2020)
7.3 Japan Inactivated Vaccine Sales and Growth Rate (2015-2020)
7.4 Korea Inactivated Vaccine Sales and Growth Rate (2015-2020)
7.5 India Inactivated Vaccine Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Inactivated Vaccine Sales and Growth Rate (2015-2020)
7.7 Australia Inactivated Vaccine Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Inactivated Vaccine Sales, Revenue and Market Share by Country
8.1.1 South America Inactivated Vaccine Sales and Market Share by Country (2015-2020)
8.1.2 South America Inactivated Vaccine Revenue and Market Share by Country (2015-2020)
8.2 Brazil Inactivated Vaccine Sales and Growth Rate (2015-2020)
8.3 Argentina Inactivated Vaccine Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Inactivated Vaccine Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Inactivated Vaccine Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Inactivated Vaccine Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2015-2020)
9.3 Turkey Inactivated Vaccine Sales and Growth Rate (2015-2020)
9.4 Egypt Inactivated Vaccine Sales and Growth Rate (2015-2020)
9.5 South Africa Inactivated Vaccine Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Inactivated Vaccine Sales and Market Share by Type (2015-2020)
10.2 Global Inactivated Vaccine Revenue and Market Share by Type (2015-2020)
10.3 Global Inactivated Vaccine Price by Type (2015-2020)
11 Global Inactivated Vaccine Market Segment by Application
11.1 Global Inactivated Vaccine Sales Market Share by Application (2015-2020)
11.2 Global Inactivated Vaccine Revenue Market Share by Application (2015-2020)
11.3 Global Inactivated Vaccine Price by Application (2015-2020)
12 Market Forecast
12.1 Global Inactivated Vaccine Sales, Revenue and Growth Rate (2021-2025)
12.2 Inactivated Vaccine Market Forecast by Regions (2021-2025)
12.2.1 North America Inactivated Vaccine Market Forecast (2021-2025)
12.2.2 Europe Inactivated Vaccine Market Forecast (2021-2025)
12.2.3 Asia-Pacific Inactivated Vaccine Market Forecast (2021-2025)
12.2.4 South America Inactivated Vaccine Market Forecast (2021-2025)
12.2.5 Middle East & Africa Inactivated Vaccine Market Forecast (2021-2025)
12.3 Inactivated Vaccine Market Forecast by Type (2021-2025)
12.3.1 Global Inactivated Vaccine Sales Forecast by Type (2021-2025)
12.3.2 Global Inactivated Vaccine Market Share Forecast by Type (2021-2025)
12.4 Inactivated Vaccine Market Forecast by Application (2021-2025)
12.4.1 Global Inactivated Vaccine Sales Forecast by Application (2021-2025)
12.4.2 Global Inactivated Vaccine Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Inactivated Vaccine Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Inactivated Vaccine Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Astellas Pharma (Japan) Basic Information, Manufacturing Base and Competitors
Table 8. Astellas Pharma (Japan) Inactivated Vaccine Major Business
Table 9. Astellas Pharma (Japan) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 10. Astellas Pharma (Japan) SWOT Analysis
Table 11. Astellas Pharma (Japan) Inactivated Vaccine Product and Services
Table 12. Astellas Pharma (Japan) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Pfizer (U.S.) Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer (U.S.) Inactivated Vaccine Major Business
Table 15. Pfizer (U.S.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 16. Pfizer (U.S.) SWOT Analysis
Table 17. Pfizer (U.S.) Inactivated Vaccine Product and Services
Table 18. Pfizer (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. GlaxoSmithKline (U.K.) Basic Information, Manufacturing Base and Competitors
Table 20. GlaxoSmithKline (U.K.) Inactivated Vaccine Major Business
Table 21. GlaxoSmithKline (U.K.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 22. GlaxoSmithKline (U.K.) SWOT Analysis
Table 23. GlaxoSmithKline (U.K.) Inactivated Vaccine Product and Services
Table 24. GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. CSL Limited (Australia) Basic Information, Manufacturing Base and Competitors
Table 26. CSL Limited (Australia) Inactivated Vaccine Major Business
Table 27. CSL Limited (Australia) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 28. CSL Limited (Australia) SWOT Analysis
Table 29. CSL Limited (Australia) Inactivated Vaccine Product and Services
Table 30. CSL Limited (Australia) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Merck & Co (U.S.) Basic Information, Manufacturing Base and Competitors
Table 32. Merck & Co (U.S.) Inactivated Vaccine Major Business
Table 33. Merck & Co (U.S.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 34. Merck & Co (U.S.) SWOT Analysis
Table 35. Merck & Co (U.S.) Inactivated Vaccine Product and Services
Table 36. Merck & Co (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Emergent BioSolutions (U.S.) Basic Information, Manufacturing Base and Competitors
Table 38. Emergent BioSolutions (U.S.) Inactivated Vaccine Major Business
Table 39. Emergent BioSolutions (U.S.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 40. Emergent BioSolutions (U.S.) SWOT Analysis
Table 41. Emergent BioSolutions (U.S.) Inactivated Vaccine Product and Services
Table 42. Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Serum Institute of India Pvt (India) Basic Information, Manufacturing Base and Competitors
Table 44. Serum Institute of India Pvt (India) Inactivated Vaccine Major Business
Table 45. Serum Institute of India Pvt (India) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 46. Serum Institute of India Pvt (India) SWOT Analysis
Table 47. Serum Institute of India Pvt (India) Inactivated Vaccine Product and Services
Table 48. Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. MedImmune (U.S.) Basic Information, Manufacturing Base and Competitors
Table 50. MedImmune (U.S.) Inactivated Vaccine Major Business
Table 51. MedImmune (U.S.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 52. MedImmune (U.S.) SWOT Analysis
Table 53. MedImmune (U.S.) Inactivated Vaccine Product and Services
Table 54. MedImmune (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Johnson & Johnson (U.S.) Basic Information, Manufacturing Base and Competitors
Table 56. Johnson & Johnson (U.S.) Inactivated Vaccine Major Business
Table 57. Johnson & Johnson (U.S.) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 58. Johnson & Johnson (U.S.) SWOT Analysis
Table 59. Johnson & Johnson (U.S.) Inactivated Vaccine Product and Services
Table 60. Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Sanofi Pasteur (France) Basic Information, Manufacturing Base and Competitors
Table 62. Sanofi Pasteur (France) Inactivated Vaccine Major Business
Table 63. Sanofi Pasteur (France) Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 64. Sanofi Pasteur (France) SWOT Analysis
Table 65. Sanofi Pasteur (France) Inactivated Vaccine Product and Services
Table 66. Sanofi Pasteur (France) Inactivated Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Inactivated Vaccine Sales by Manufacturer (2018-2019) (K MT)
Table 68. Global Inactivated Vaccine Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Inactivated Vaccine Sales by Regions (2015-2020) (K MT)
Table 70. Global Inactivated Vaccine Sales Market Share by Regions (2015-2020)
Table 71. Global Inactivated Vaccine Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Inactivated Vaccine Sales by Countries (2015-2020) (K MT)
Table 73. North America Inactivated Vaccine Sales Market Share by Countries (2015-2020)
Table 74. North America Inactivated Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 76. Europe Inactivated Vaccine Sales by Countries (2015-2020) (K MT)
Table 77. Europe Inactivated Vaccine Sales Market Share by Countries (2015-2020)
Table 78. Europe Inactivated Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Inactivated Vaccine Sales by Regions (2015-2020) (K MT)
Table 80. Asia-Pacific Inactivated Vaccine Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Inactivated Vaccine Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Inactivated Vaccine Sales by Countries (2015-2020) (K MT)
Table 83. South America Inactivated Vaccine Sales Market Share by Countries (2015-2020)
Table 84. South America Inactivated Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Inactivated Vaccine Sales by Countries (2015-2020) (K MT)
Table 87. Middle East & Africa Inactivated Vaccine Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Inactivated Vaccine Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 90. Global Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 91. Global Inactivated Vaccine Sales Share by Type (2015-2020)
Table 92. Global Inactivated Vaccine Revenue by Type (2015-2020) (USD Million)
Table 93. Global Inactivated Vaccine Revenue Share by Type (2015-2020)
Table 94. Global Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 95. Global Inactivated Vaccine Sales Share by Application (2015-2020)
Table 96. Global Inactivated Vaccine Sales Forecast by Regions (2021-2025) (K MT)
Table 97. Global Inactivated Vaccine Market Share Forecast by Regions (2021-2025)
Table 98. Global Inactivated Vaccine Sales Forecast by Type (2021-2025) (K MT)
Table 99. Global Inactivated Vaccine Market Share Forecast by Type (2021-2025)
Table 100. Global Inactivated Vaccine Sales Forecast by Application (2021-2025)
Table 101. Global Inactivated Vaccine Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Inactivated Vaccine Picture
Figure 2. Global Sales Market Share of Inactivated Vaccine by Type in 2019
Figure 3. Inactivated Vaccine Sales Market Share by Application in 2018
Figure 4. Hospital Picture
Figure 5. Medical Center Picture
Figure 6. Global Inactivated Vaccine Market Status and Outlook (2015-2025) (USD Million)
Figure 7. United States Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 8. Canada Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 9. Mexico Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 10. Germany Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 11. France Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 12. UK Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Russia Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Italy Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 15. China Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Japan Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Korea Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 18. India Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Southeast Asia Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Australia Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 21. Brazil Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Egypt Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Saudi Arabia Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 24. South Africa Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Turkey Inactivated Vaccine Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Global Inactivated Vaccine Sales Market Share by Manufacturer in 2019
Figure 27. Global Inactivated Vaccine Revenue Market Share by Manufacturer in 2019
Figure 28. Top 3 Inactivated Vaccine Manufacturer (Revenue) Market Share in 2019
Figure 29. Top 6 Inactivated Vaccine Manufacturer (Revenue) Market Share in 2019
Figure 30. Key Manufacturer Market Share Trend
Figure 31. Global Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 32. Global Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 33. Global Inactivated Vaccine Revenue Market Share by Regions (2015-2020)
Figure 34. Global Inactivated Vaccine Revenue Market Share by Regions in 2018
Figure 35. North America Inactivated Vaccine Sales and Growth Rate (2015-2020)
Figure 36. Europe Inactivated Vaccine Sales and Growth Rate (2015-2020)
Figure 37. Asia-Pacific Inactivated Vaccine Sales and Growth Rate (2015-2020)
Figure 38. South America Inactivated Vaccine Sales and Growth Rate (2015-2020)
Figure 39. Middle East & Africa Inactivated Vaccine Sales and Growth Rate (2015-2020)
Figure 40. North America Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. North America Inactivated Vaccine Sales Market Share by Countries (2015-2020)
Figure 42. North America Inactivated Vaccine Sales Market Share by Countries in 2018
Figure 43. North America Inactivated Vaccine Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 44. North America Inactivated Vaccine Revenue Market Share by Countries in 2018
Figure 45. United States Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 46. Canada Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 47. Mexico Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 48. Europe Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. Europe Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 50. Europe Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 51. Germany Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 52. UK Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 53. France Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 54. Russia Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 55. Italy Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 56. Asia-Pacific Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Asia-Pacific Inactivated Vaccine Sales Market Share by Regions 2019
Figure 58. Asia-Pacific Inactivated Vaccine Revenue Market Share by Regions 2019
Figure 59. China Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 60. Japan Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 61. Korea Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 62. India Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 63. Southeast Asia Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 64. South America Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. South America Inactivated Vaccine Sales Market Share by Countries in 2019
Figure 66. South America Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 67. Brazil Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 68. Argentina Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 69. Middle East and Africa Inactivated Vaccine Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. Middle East and Africa Inactivated Vaccine Sales Market Share by Countries in 2019
Figure 71. Middle East and Africa Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 72. Middle East and Africa Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 73. Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 74. Egypt Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 75. Turkey Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 76. South Africa Inactivated Vaccine Sales and Growth Rate (2015-2020) (K MT)
Figure 77. Global Inactivated Vaccine Sales and Growth Rate (2021-2025) (K MT)
Figure 78. Global Inactivated Vaccine Revenue and Growth Rate (2021-2025) (USD Million)
Figure 79. North America Sales Inactivated Vaccine Market Forecast (2021-2025) (K MT)
Figure 80. Europe Sales Inactivated Vaccine Market Forecast (2021-2025) (K MT)
Figure 81. Asia-Pacific Sales Inactivated Vaccine Market Forecast (2021-2025) (K MT)
Figure 82. South America Sales Inactivated Vaccine Market Forecast (2021-2025) (K MT)
Figure 83. Middle East & Africa Sales Inactivated Vaccine Market Forecast (2021-2025) (K MT)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel
麻疹ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Measle Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Measle Vaccine market report p…- ライム病ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Lyme Disease Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Lyme Disease Vaccine mar…
- ヒト用予防ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Prophylactic Human Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Prophylactic Human…
- 食用ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Edible Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Edible Vaccine market report p…
- エボラウイルスワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Ebola Virus Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ebola Virus Vaccine marke…